A company that wins a bid to sell pharmaceuticals to the government but then claims it is unable to fulfill the complete order is the source of a series of problems in Mexico. This forces public hospitals to make emergency purchases at much higher prices, which directly affects patients and increases the cost of the healthcare system. There have even been cases where the non-compliant company "passes" the medications to another distributor to sell them at higher prices, favoring companies like Poyago and Rimisa Medical and worsening the supply crisis.
In terms of structured cabling, Panduit, under the direction of Carlos Arochi in Mexico and LATAM, has proven to be a leader in Latin America. During the year 2024, they achieved a growth of 9.4% in the region and 6.5% in Mexico. This success is due to the growing demand in data centers, manufacturing, and industry, with key regions such as Bajío and northern Mexico. Additionally, five projects of over 2 million dollars have been finalized in LATAM and the company has exceeded targets for 17 consecutive quarters.
Behind this crisis in the healthcare sector are concerning practices that demand an immediate response from the relevant authorities. For example, cases such as that of Poyago, which sold essential medications to IMSS last year at markups of up to 1,000%. It is essential that these irregularities be investigated and sanctioned to guarantee the right to health for Mexicans.
In the field of plastics, the National Association of Plastic Industries (ANIPAC) is preparing for its Perspectives 2025 forum. This event will showcase financial, political, and economic trends at the national and international level, as well as the challenges facing the sector in the Asian market and in the United States. This forum will feature the participation of experts in the field and will address relevant themes for the plastics industry in Mexico.
Despite the fact that plastic is an economical material, in Mexico there is still a stigma attached to it, even though approximately 7 million tons are consumed annually. Recent mobilizations by health sector workers have once again highlighted the problem of medication shortages in public hospitals, being concerning that despite indications, contracts continue to be extended to companies like Amarox.
